OHE https://validator.w3.org/feed/docs/rss2.html Invest to End TB. Save Lives. World TB Day 2022. Reflections on 60 years of OHE publications on TB OHE Ethical Goals and Design Criteria for ‘Fair Access” to Drugs in the US Health Care System Let’s talk about (health) inequalities Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions? Key Learnings From COVID-19: The Importance of Portfolio Management and How to Procure, Pay For, Distribute, and Use Vaccines During a Pandemic Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far? Accounting for Preference Heterogeneity in Discrete Choice Experiments Would Waiving COVID-19 Vaccines Patents Save Lives? Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere? Towards a New Understanding of Unmet Medical Need Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate Open Source Modelling: From Ideas to Action How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine? Where are we 6 Months on? The CBO Doesn’t Understand Investors New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof) CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation  The cost of inaction on LDL cholesterol Rare Disease Day 2022 To Hell with the 3L! NICE’s Missed Opportunity to Upgrade Health Outcome Measurement No Smoking Day 2022: Reflecting on OHE Projections from 1994 Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet? The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed? NICE’s severity modifier: a step in the right direction, but still a long way to go H.R. 3 is the Wrong Policy for the Wrong Problem Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients. Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office Does the New CBO Report Change Anything? OHE is Launching a New Series to Explore the Latest Attempts to Reduce the Cost of US Healthcare Sleepio: Lessons from the Frontier of Digital Therapeutics ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies? The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis The State of Play for Cost-effectiveness Thresholds Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order Atherosclerotic cardiovascular disease (ASCVD) costs the world $680 billion a year in healthcare – roughly the size of Sweden’s entire economy, new research finds  Kefah Al Qawasmeh  Haider Shamsi Can HTA keep up with innovation? A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List” How Does Pharmaceutical Spending Drive Innovation in Europe? A Dose of Economics Mid-year health check: policy, pricing & what’s coming The disputed calculus of life Brendan Shaw Gundo Weiler Cost-effectiveness thresholds: theory, pragmatism, and NICE’s new number What is your health worth? PROMs, EQ-5D & economic evaluation Our team Hannah Hussain